Bioenergetic data from a creatine monohydrate pilot trial in Alzheimer's disease
Abstract BACKGROUND Creatine monohydrate (CrM) may mitigate bioenergetic failure in Alzheimer's disease (AD) by supporting ATP buffering and modulating mitochondrial function. Building upon our previous findings that CrM is associated with increased brain creatine (Cr) and improved cognition in AD,...
Gorde:
| Egile Nagusiak: | , , , , , , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Wiley
2026-01-01
|
| Saila: | Alzheimer’s & Dementia: Translational Research & Clinical Interventions |
| Gaiak: | |
| Sarrera elektronikoa: | https://doi.org/10.1002/trc2.70228 |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|